HomeFilePharmacology

Pharmacology

Are Elevated Lipoprotein (a) Levels Associated with Increased Adverse Events After Peripheral Endovascular Treatment?

Peripheral arterial disease is a manifestation of systemic atherosclerotic disease with increasing prevalence. Moreover, this disease is...

Antithrombotic Therapy Post Percutaneous Left Atrial Appendage Closure

Percutaneous left atrial appendage closure (LAAO) with Watchman has FDA approval since March 2015, having shown, in...

An Abbreviated Dual Antiplatelet Regimen Is Also Safe in Patients at High Risk for Bleeding Undergoing Complex Angioplasty

The MASTER DAPT study analyzed the results of an abbreviated (mean 34 days) vs. conventional dual antiplatelet...

High Risk of Bleeding after PCI: More Evidence for Short DAPT

Dual antiaggregation therapy (DAPT) with ASA and P2Y12 during 6 to 12 months is the indicated strategy...

Two Safe Stents at Two Years in High Bleeding Risk

There is a consistent number of patients presenting high risk of bleeding. In this context, receiving dual...

Safety of Acetylcholine in the Cath Lab

The concepts of ischemia with non-obstructive coronary artery disease (INOCA) and myocardial infarction with non-obstructive coronary artery...

Results of Zotarolimus-Eluting Stents vs Biolimus-Eluting Polymer-Free Stents After 2 Years. Are They Safe in Patients at High Risk for Bleeding?

The proportion of patients treated with coronary angioplasty who are at a high risk for bleeding is...

Prophylactic Rivaroxaban Therapy for Left Ventricular Thrombus after ST-Segment Elevation Acute Coronary Syndrome

The incidence of left ventricular thrombosis (LVT) after anterior ST-segment elevation myocardial infarction (STEMI) ranges from 4%...